Navigation Links
CardioWest™ Artificial Heart Approved For Highest Reimbursement in CMS History : Plus Up To $53,000 New Technology Add-on Payments
Date:8/7/2008

On July 31, the Centers for Medicare and Medicaid Services (CMS) issued its final decision to reimburse the CardioWest temporary Total Artificial Heart (TAH-t) through the highest paying Diagnostic Related Group codes, MS-DRG 001 and 002. In addition, CMS also approved the CardioWest artificial heart for new technology add-on payments for FY 2009, which starts Oct. 1, 2008.

TUCSON, Ariz. (Business Wire EON) August 7, 2008 -- On May 1, 2008, CMS reversed its 1986 non-coverage policy for artificial hearts and approved Medicare reimbursement for the CardioWest artificial heart when implanted as part of an FDA study that meets CMS specifications. For more than two decades prior to this decision, Medicare denied reimbursement for the CardioWest artificial heart.

In the July 31 decision, CMS agreed that, "the TAH-t fulfills a role that no other mechanical circulatory support device can for patients in irreversible biventricular failure."

The thresholds for new technology add-on payments for MS-DRGs 001 and 002 are $345,031 and $178,142 respectively and are retroactive to May 1, 2008. CMS also finalized a new technology add-on payment for the CardioWest artificial heart of up to $53,000, starting Oct. 1, 2008.

"We continue to believe that the TAH-t meets the newness criterion despite having received FDA approval more than three years ago because it was not covered by Medicare until May 1, 2008," the CMS decision stated.

"This decision helps ensure that our hospitals receive adequate reimbursement for the life-saving artificial heart technology they provide," said Rodger Ford, CEO and president of SynCardia Systems, Inc., manufacturer of the CardioWest artificial heart. "In the past, hospitals and their patients have experienced great success with our device, but hospitals risked taking substantial economic losses in order to bridge these patients to transplant. Now, our certified centers can afford to save thousands of end stage heart failure patients."

Originally designed as a permanent replacement heart, the CardioWest artificial heart is currently approved as a bridge to human heart transplant for patients dying from end stage biventricular failure. These patients are often days, if not hours from death. Their survival is dependent upon receiving a matching donor heart, or a CardioWest artificial heart as a bridge-to-transplant.

The CardioWest artificial heart is the first and only FDA, Health Canada and CE Mark approved temporary Total Artificial Heart in the world. There have been more than 740 implants of the CardioWest, accounting for more than 135 patient years of life on the artificial heart.

In the 10-year pivotal clinical study of the CardioWest artificial heart (New England Journal of Medicine 2004; 351: 859-867), 79 percent of patients receiving the CardioWest survived to transplant. This is the highest bridge-to-transplant rate for any heart device in the world.

MULTIMEDIA GALLERYhttp://www.businesswire.com/cgi-bin/mmg.cgi?eid=5750701

Read the full story at http://www.prweb.com/releases/cardiowest/heart/prweb1189654.htm


'/>"/>
Source: PRWeb
Copyright©2008 Vocus, Inc.
All rights reserved  

Related biology technology :

1. MIT: Leveraging learning for artificial respiration
2. MIT: Leveraging learning for artificial respiration
3. DNA sensors found to be an effective artificial nose
4. Memory in artificial atoms
5. Stretchable silicon camera next step to artificial retina
6. Thoratec Announces HeartMate II(R) PMA Will be Reviewed by FDA Advisory Panel
7. ATS Medical Expands Open Pivot Heart Valve Offerings
8. Cardicas C-Port(R) Flex A Anastomosis System Allows Surgeons to Perform Revolutionary Closed-Chest Heart Bypass Surgeries
9. Signalifes Dr. Harmison Launches Award-Winning Ambulatory Heart Monitor
10. Cleveland Clinic-Led Research Uncovers New Mechanism That Heightens Risk of Heart Disease
11. New Licence for Cubicin(R) (daptomycin), the First in a Novel Class of Antibiotic, is Announced Today for the Treatment of Serious Bloodstream and Heart Infections Caused by the Most Problematic UK Organisms, Including MRSA
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
 CardioWest™ Artificial Heart Approved For Highest Reimbursement in CMS History :  Plus Up To $53,000 New Technology Add-on Payments 
(Date:4/20/2017)... ... April 20, 2017 , ... NetDimensions appoints Bill Mastin, ... With over 20 years of experience in the learning technologies industry, Mastin joins NetDimensions ... within Learning Technologies Group plc (LTG). At LEO, Mastin served as SVP of the ...
(Date:4/20/2017)... ... April 20, 2017 , ... Open Therapeutics ... property (IP) sharing and commercialization model. , The Center for Advancing Innovation helps ... of this effort is bringing the IP to the attention of the entrepreneurial ...
(Date:4/19/2017)... ... , ... The Vibrating Orifice Aerosol Generator (VOAG) was developed ... of known diameters for research applications such as for calibrating droplet measuring instruments, ... droplets. , The VOAG requires forcing liquid out of an orifice about ...
(Date:4/19/2017)... ... 19, 2017 , ... Nobilis Therapeutics Announces Completion of Landmark NBTX-001 ... Data in its Upcoming Post Traumatic Stress Disorder Trial , Nobilis Therapeutics, Inc. ... assessing efficacy of its NBTX-001, a xenon-based therapeutic in the treatment of Panic Disorder. ...
Breaking Biology Technology:
(Date:3/29/2017)... the health IT company that operates the largest health ... today announced a Series B investment from BlueCross BlueShield ... investment and acquisition accelerates higi,s strategy to create the ... activities through the collection and workflow integration of ambient ... secures data today on behalf of over 36 million ...
(Date:3/27/2017)... 27, 2017  Catholic Health Services (CHS) has ... Society (HIMSS) Analytics for achieving Stage 6 on ... . In addition, CHS previously earned a place ... an electronic medical record (EMR). "HIMSS ... of EMR usage in an outpatient setting.  This ...
(Date:3/24/2017)... , Mar 24, 2017 Research and ... Access System Market Analysis & Trends - Industry Forecast to 2025" ... ... to grow at a CAGR of around 15.1% over the next ... This industry report analyzes the market estimates and forecasts for all ...
Breaking Biology News(10 mins):